Arrowpoint Investment Partners Singapore Pte. Ltd. Makes New Investment in Eli Lilly and Company $LLY

Key Points

• Arrowpoint Investment Partners Singapore initiated a new position in Eli Lilly during the fourth quarter, buying 9,193 shares worth about $9.88 million. The stake makes LLY its 15th-largest holding and about 1.5% of its portfolio.
• Eli Lilly shares rose 4.3% and were trading near their 52-week high at $1,125.00. The company now has a market cap of about $1.06 trillion, underscoring the stock’s strong momentum.
• Lilly continues to report strong fundamentals, with its latest quarter showing EPS of $8.55 versus $6.97 expected and revenue of $19.8 billion, up 55.5% year over year. The company also reaffirmed bullish guidance for FY 2026 and declared a quarterly dividend of $1.73 per share.

Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in Eli Lilly and Company (NYSE:LLY - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 9,193 shares of the company's stock, valued at approximately $9,880,000. Eli Lilly and Company comprises approximately 1.5% of Arrowpoint Investment Partners Singapore Pte. Ltd.'s portfolio, making the stock its 15th biggest holding.

A number of other institutional investors have also added to or reduced their stakes in LLY. Brighton Jones LLC boosted its holdings in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after purchasing an additional 40 shares in the last quarter. Schnieders Capital Management LLC. boosted its holdings in shares of Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company's stock worth $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $356,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $749,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 4.3%

LLY stock opened at $1,125.00 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,149.10. The business's 50 day moving average price is $970.24 and its two-hundred day moving average price is $1,012.19. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The company has a market capitalization of $1.06 trillion, a price-to-earnings ratio of 39.96, a price-to-earnings-growth ratio of 1.18 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the business earned $3.34 EPS. The business's revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's payout ratio is currently 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly signed a collaboration and licensing deal with Ascidian Therapeutics worth up to $1.9 billion to develop RNA-based kidney-disease therapies, reinforcing its strategy of using GLP-1 cash flow to broaden the pipeline. Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
• Positive Sentiment: Management signaled that more M&A may be coming, which investors view as a way to reduce reliance on obesity drugs and build new long-term growth engines. Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
• Positive Sentiment: Multiple articles highlighted Lilly as a stock to own, citing its strong GLP-1 franchise and broader pipeline momentum across gene editing, vaccines, and cancer. 3 Reasons Eli Lilly Remains a Buy
• Neutral Sentiment: Weight Watchers expanded access to its program through LillyDirect, which reinforces Lilly’s ecosystem around GLP-1 drugs but is not a direct financial catalyst on its own. Weight Watchers Expands Reach Through LillyDirect Partnership (WW)
• Neutral Sentiment: Technical/market commentary also turned favorable, with one note saying Lilly flashed two buy signals, adding to the bullish sentiment around the name. Eli Lilly, IBD Stock Of The Day, Flashes Two Buy Signals
• Negative Sentiment: Broader market weakness from a selloff in AI/tech sentiment could create some cross-asset pressure, though this is not specific to Lilly’s fundamentals. Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Scotiabank reiterated an "outperform" rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Berenberg Bank increased their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a "hold" rating in a report on Thursday, February 19th. Morgan Stanley restated an "overweight" rating and issued a $1,344.00 price objective on shares of Eli Lilly and Company in a research report on Friday, May 1st. HSBC lowered Eli Lilly and Company from a "hold" rating to a "reduce" rating and lowered their price target for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Finally, Wells Fargo & Company upped their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus target price of $1,227.00.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.